Skip to main content

CooperCompanies Announces New Board Appointments

Written by Customer Service on . Posted in Public Companies.

SAN RAMON, Calif., March 24, 2021 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO) announced today that its Board of Directors elected Robert S. Weiss as Chairman of the Board and William A. Kozy as Vice Chairman and Lead Director. Both appointments are effective March 23, 2021.

“Bob and Bill’s broad management experience and deep knowledge of the medical device industry is incredibly valuable as we continue to grow the business,” said Al White, Cooper’s President and CEO. “I look forward to working closely with them in their new roles to ensure Cooper continues to have a positive impact on all our stakeholders.”

Mr. Weiss has served on the CooperCompanies Board since 1996. He succeeds A. Thomas Bender as Chairman of the Board. After a long and distinguished career with Cooper, which included serving as President and CEO from 1995 to 2007 and Chairman from 2002 to March 2021, Mr. Bender announced his retirement from the Board in December 2020.

Mr. Weiss held several leadership positions with Cooper during his career. He served as President of CooperCompanies from March 2008 and as CEO from November 2007 until his retirement in May 2018. Prior to that, he served as Chief Operating Officer of CooperCompanies from 2005 to 2007 and as Executive Vice President from 1995 to 2007. Earlier, he served as Chief Financial Officer from 1989 to 2005 and Treasurer from 1989 to 2002.

Mr. Kozy was first elected to the CooperCompanies Board in 2016. He succeeds Allan E. Rubenstein, M.D., as Vice Chairman and Lead Director. Dr. Rubenstein announced his retirement from the Board in December 2020 after many positive years supporting the Company’s growth initiatives.

Mr. Kozy served as the Chief Operating Officer of Becton Dickinson from 2012 until his retirement in 2016 and as its Executive Vice President from 2006 until 2016. He also served as a member of the Corporate Leadership Team for Becton Dickinson and in various executive roles since 1988, including Senior Vice President of Company Operations, President of BD Diagnostics, President of the BD Biosciences segment, and head of BD Medical.

About CooperCompanies
CooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies, and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

CONTACT:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.